“Explore the Castrate‑Resistant Prostate Cancer therapeutics market—valued at ~$13 B in 2024, forecast to $33 B by 2035 (CAGR ~8.8%). Includes therapy segments, key drugs (enzalutamide, pembrolizumab), and regional trends.” https://www.datamintelligence.com/research-report/castrate-resistant-prostate-cancer-therapeutics-market